An oral dose of Fluralaner administered to dogs kills pyrethroid-resistant and susceptible Chagas disease vectors for at least four months

Publication date: Available online 18 March 2019Source: Veterinary ParasitologyAuthor(s): M.A. Laiño, M.V. Cardinal, G.F. Enriquez, A. Alvedro, M.S. Gaspe, R.E. GürtlerABSTRACTNew vector control tools that can fit into a broader integrated vector management strategy are notably lacking. We conducted a seven-month randomized trial to assess the efficacy of a single oral dose of Fluralaner (Bravecto®) administered to dogs on the blood-feeding success, engorgement levels and mortality of pyrethroid-resistant and -susceptible Triatoma infestans third- and fifth-instar nymphs. The trial included 10 Fluralaner-treated and 10 placebo-treated (control) outbred healthy dogs residing in rural houses of the Argentine Chaco. Most (92.7%) of the 3,017 triatomines exposed were able to blood-feed. Generalized linear models showed that blood-feeding success was not significantly modified by Fluralaner treatment, time posttreatment and their interaction. However, pyrethroid-susceptible fifth instars blood-fed significantly more frequently than susceptible third instars, and no significant differences were observed between the latter and resistant fifth instars. Engorgement levels were not significantly modified by Fluralaner treatment, time posttreatment and their interaction. Nearly all the triatomines that blood-fed on treated dogs up to 60 days posttreatment (DPT) died within 24 h regardless of pyrethroid susceptibility status combined with bug stage. Cumulative bug ...
Source: Veterinary Parasitology - Category: Veterinary Research Source Type: research

Related Links:

AbstractPurpose of ReviewEstimates of Chagas disease (CD) seroprevalence in the Americas vary greatly. We lack an accurate representation of the state of the disease in this region for various reasons including intranational variability in prevalence and a lack of standardized diagnostic approaches. The goal of this review is to generate an estimate of CD burden in the Americas, by performing a systematic review of recent prevalence papers published after major vector control initiatives.Recent FindingsCommunity-based CD screening programs that focus on a third- to fourth-level administrative division basis are more repres...
Source: Current Tropical Medicine Reports - Category: Tropical Medicine Source Type: research
Fogo Selvagem (FS) is a lethal skin disease mediated by pathogenic IgG4 autoantibodies to desmoglein-1 (Dsg1). FS is prevalent in certain regions of Brazil, where Leishmaniasis and Chagas disease are endemic. Normal individuals and leishmaniasis patients from these regions possess non-pathogenic anti-Dsg1 antibodies. They are chronically exposed to bites of the sand fly Lutzomyia longipalpis (LL), which elicits an IgG response to LL salivary proteins LJM17 and LJM11 and could contribute to the development of FS.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Adaptive and Auto-Immunity Source Type: research
Abstract Trypanossoma cruzi (T. cruzi), the causative protozoan of Chagas disease (CD) invades many cell types, including central nervous system (CNS) cells triggering local lesions and neurological impact. Previous work from our group described NLRP3 inflammasomes as central effectors for the parasite control by macrophages. Recent evidences demonstrate that NLRP3 can be activated in CNS cells with controversial consequences to the control of infections and inflammatory pathologies. However, the relative contribution of NLRP3 in different cell types remains to be elucidated. In this article, we described an effec...
Source: Journal of Leukocyte Biology - Category: Hematology Authors: Tags: J Leukoc Biol Source Type: research
Conclusions: We suggest some distinct molecular mechanisms for production of IL-1β in innate immune cells from patients with different clinical forms of Chagas disease. MMP-2 and MMP-9 gelatinases are associated with distinct disease outcomes and IL-1β production. Introduction Chagas disease, also known as American trypanosomiasis, is a neglected parasitic disease caused by the protozoan Trypanosoma cruzi (1), that affects millions of people in the world (2). During the acute phase, a diffuse and intense inflammation in the cardiomyocytes is observed, which is composed mainly of neutrophils, monocytes, and ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
AbstractPurpose of ReviewChagas disease is endemic to all seven Central American countries, where 12% of the population lives in areas where the disease is a risk. While neglect is a pervasive characteristic of Chagas disease in general, it tends to be especially overlooked in Central America, with more studies and resources devoted to the disease in South America. Here we report on the current epidemiological scenario of Chagas disease in Central America with the objective of presenting a panorama that includes national program details, recent morbidity data, new findings, and events relevant to the disease.Recent Finding...
Source: Current Tropical Medicine Reports - Category: Tropical Medicine Source Type: research
In this study, collectin-11 plasma levels andCOLEC11 variants in exon 7 were assessed in a Brazilian cohort of 251 patients with chronic CD and 108 healthy controls. Gene-gene interactions betweenCOLEC11 andMASP2 variants were analyzed. Collectin-11 levels were significantly decreased in CD patients compared to controls (p
Source: PLoS Neglected Tropical Diseases - Category: Tropical Medicine Authors: Source Type: research
A growing public health threat demands more awareness of Chagas disease and its manifestations.Medscape Infectious Diseases
Source: Medscape Infectious Diseases Headlines - Category: Infectious Diseases Tags: Infectious Diseases Case Challenge Source Type: news
(JPA Health) Atomwise Inc., a biotech company using artificial intelligence (AI) for drug discovery, and the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development organization working to deliver new treatments for neglected diseases, today announced that promising drug-like compounds have been discovered in a program to develop first-in-class treatments for Chagas disease. The research collaboration is part of Atomwise's Artificial Intelligence Molecular Screen (AIMS) Awards program.
Source: EurekAlert! - Biology - Category: Biology Source Type: news
Dalton Trans., 2019, Accepted Manuscript DOI: 10.1039/C9DT01317B, PaperEsteban Rodriguez Arce, Eugenia Putzu, Michel Lapier, Juan Diego Maya, Claudio Olea-Azar, Gustavo Etcheverria, Oscar E. Piro, Andrea Medeiros, Florencia Sardi, Marcelo Comini, Gast ón Risi, Gustavo Salinas, Isabel Correia, João Pessoa, Lucía Otero, Dinorah Gambino In the search for a more effective chemotherapy for the treatment of Chagas disease and Human African trypanosomiasis, caused by Trypanosoma cruzi and Trypanosoma brucei parasites, respectively, the use of... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Dalton Trans. latest articles - Category: Chemistry Authors: Source Type: research
In this study, the expression of the CPR gene at transcriptional level was determined in different tissues and two life stages. The expression patterns showed differences in the tissues and stages studied, suggesting differential metabolic requirements. On the other hand, to investigate the presence of rhythms in the expression of genes related with insecticide resistance, we explored the daily expression profile of the CPR gene and a P450 gene (CYP4EM7) in fat body from adults of T. infestans under different dark/light regimes. The results suggest that CPR gene expression is under endogenous clock regulation and show a rh...
Source: The American Journal of Tropical Medicine and Hygiene - Category: Tropical Medicine Authors: Tags: Am J Trop Med Hyg Source Type: research
More News: Chagas Disease | Parasitology | Rural Health | Veterinary Research